Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : son of T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (32)	8/16/1999 10:44:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 673

The first day of Drug Discovery is behind us... seems not to be doing much for my micros--but this ain't asco...still you never know. I've posted this at least once before, sorry about the repeat if you're getting bored with this... MON 11:05 Gene Expression Profiling and Its Use in Drug Discovery and Predictive Toxicology Greg Lennon, Ph.D. Gene Logic is using the combined power of open and closed system gene expression technologies to develop large-scale expression databases. The mining of such large expression databases for the purpose of discovering new drug targets and for studying the effects of drugs currently in use will be discussed. For toxicologic studies, we are focusing initially on liver gene expression profiles because the liver is the dominant target site of specific toxins. Studies performed in collaboration with Wyeth-Ayerst Research have utilized both liver samples exposed in vivo to well-recognized toxins and hepatocytes exposed in vitro to the same toxins. Our studies have demonstrated alterations in known toxic response genes (such as cytochrome P450 reductases), changes in genes whose participation in toxic events have been unrecognized to-date, and just as significantly, alterations in the expression of hitherto unknown (i.e. novel) genes. We will discuss this data and ongoing efforts to study additional tissues and organs cooperatively with multiple pharmaceutical partners. Doesn't look like any of the scientists ran out of the auditorium at lunch time to load up on stock <g> Lets see if Mr. Schreiber has anything to say about Ariad on Tuesday... TUE 8:50 Specificity and Generality in Chemical Genetic Research Stuart L. Schreiber, Ph.D., Co-Director, Harvard Institute of Chemistry & Cell Biology, Harvard University Transcription profiling using DNA chips allows the specificity of small molecules to be assessed in a semi-quantitative way for the first time. We have used this method to show that the specificity of a small molecule approaches that of a deletion mutant, where the gene encoding the small molecule receptor is inactivated. Chemical genetic studies aimed at exploring signal transduction, the role of chromatin in gene regulation and the role of PIK-related kinases in cell cycle checkpoints are underway. We have undertaken two approaches to generalize chemical genetics. One approach uses small molecule dimerizers, which allow for the study of function of proteins for which small molecule ligands are not known. The second approach uses our ability to emulate many aspects of genetic principles to discover small molecule ligands, which could lead to a small molecule partner for every gene product. --by the way, I finally figured out what the paragraph in the Ariad annual about Cornell and Jon Clardy is probably about (google.com is so great) FRAP. Someday I'll have a pretty good feel for this stock...certainly by the time it is delisted <g> _________________ Mr. Green Genes techstocks.com Monopoly money burns a hole in your pocket even faster than the real stuff!

To: LLCF who wrote (32)	8/16/1999 10:47:00 PM
From: scaram(o)uche	Respond to of 673

Dave and Mike: Thanks for the portfolios! Allows continuation of a good thread tradition. Would you mind posting the links to the thread on occasion, just so we don't have to go hunting and pecking for it? I'd use newbies as an excuse, but I think everyone is familiar with my organization skills. At this point in a rally, one needs to "feel" their way around market capitalizations. Lots of what we call "second-tiers" have moved to a market cap that used to constitute first-tier status. My portfolio has been going bonkers all year. Good stock picking mixed with timing luck up my wazoo. I can spin gold it seems, even without Miljenko, push come to shove (he's been busy with a home remodel). Nonetheless, it drives me nuts to think that I could have beaten my performance by far with near-the-money calls in first- and second-tier companies. We need to cross a day-trader billionaire with Harold during the early stages of the next rally (if this one ever stops). Good science that is not connected with a phase III trial is, IMO, a good place to go looking for a combination of relative safety and zoom potential. Hey, this is son of T/FIF...... may as well be wrong twice. :-) Good luck, all, and a hip hip hooray or two for Dave and Mike! Rick